Loading clinical trials...
Loading clinical trials...
Bearers of the sickle cell allele (S) are currently eligible for blood donations in Belgium. As blood donors are not tested for this allele, their heterozygous status is unknown. However, guidelines recommend to transfuse sickle cell patients with blood that is negative for the 'S' hemoglobin. To the investigator's knowledge, no study has been conducted to evaluate the impact of transfusion with blood originating from heterozygous donors on the transfusion performance and the improvement of clinical status of the sickle cell disease patients.
Age
All ages
Sex
ALL
Healthy Volunteers
No
CHU Brugmann
Brussels, Belgium
HUDERF
Brussels, Belgium
Start Date
February 13, 2018
Primary Completion Date
August 3, 2020
Completion Date
August 3, 2020
Last Updated
January 28, 2021
173
ACTUAL participants
Blood sampling
PROCEDURE
Lead Sponsor
Hanane EL KENZ
NCT05170412
NCT06526117
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06665997